Literature DB >> 9186001

Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions.

H Chen1, M A Biel, M W Borges, A Thiagalingam, B D Nelkin, S B Baylin, D W Ball.   

Abstract

Malignancies with neuroendocrine (NE) features such as medullary thyroid cancer (MTC) and small cell lung cancer (SCLC) are prototypic neoplasms arising from peripheral endocrine cells. The mechanisms that regulate the NE phenotype in these tumors and their cellular precursors are not well understood. However, a basic helix-loop-helix transcription factor that is homologous to Drosophila neural fate determination proteins may have a central role. Human achaete-scute homologue-1 (hASH1), a human homologue of the Drosophila achaete-scute complex, is highly expressed in MTC, SCLC, and pheochromocytomas. To determine what mechanisms allow constitutive expression of hASH1 in NE tumors, we cloned human genomic DNA fragments containing the hASH1 gene and characterized its promoter region. We show that hASH1 expression is restricted to NE cell lines by a transcriptionally regulated mechanism. Dual promoters initiate hASH1 transcription, with the predominant site being an evolutionarily conserved initiator (INR) element. Transient transfection studies provide evidence for a generalized enhancer region that has high activity in all cell lines tested. Restriction of hASH1 expression to NE tumor cells depends on two tissue-specific repressor regions, present in the proximal and distal (> 13.5 kb) 5'-flanking region. Understanding the mechanisms of tissue-specific control of hASH1 gene expression provides a useful model to explore regulatory cascades influencing both normal nervous system development and the NE phenotype of tumors such as MTC and SCLC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9186001

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  17 in total

Review 1.  Use of reporter genes for optical measurements of neoplastic disease in vivo.

Authors:  C H Contag; D Jenkins; P R Contag; R S Negrin
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Noninvasive assessment of tumor cell proliferation in animal models.

Authors:  M Edinger; T J Sweeney; A A Tucker; A B Olomu; R S Negrin; C H Contag
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer.

Authors:  Matthew Truong; Mackenzie R Cook; Scott N Pinchot; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Ann Surg Oncol       Date:  2010-12-24       Impact factor: 5.344

4.  EVOPRINTER, a multigenomic comparative tool for rapid identification of functionally important DNA.

Authors:  Ward F Odenwald; Wayne Rasband; Alexander Kuzin; Thomas Brody
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-03       Impact factor: 11.205

5.  Upstream stimulatory factor activates the vasopressin promoter via multiple motifs, including a non-canonical E-box.

Authors:  Judy M Coulson; Jodie L Edgson; Zoe V Marshall-Jones; Robert Mulgrew; John P Quinn; Penella J Woll
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

6.  Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Authors:  Chuan Jin; Di Yu; Matko Čančer; Berith Nilsson; Justyna Leja; Magnus Essand
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

7.  Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer.

Authors:  Mackenzie Cook; Xiao-Min Yu; Herbert Chen
Journal:  Am J Transl Res       Date:  2010-02-10       Impact factor: 4.060

8.  Xanthohumol inhibits the neuroendocrine transcription factor achaete-scute complex-like 1, suppresses proliferation, and induces phosphorylated ERK1/2 in medullary thyroid cancer.

Authors:  Mackenzie R Cook; Jie Luo; Mary Ndiaye; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Am J Surg       Date:  2010-03       Impact factor: 2.565

Review 9.  The growth factor independence-1 transcription factor: new functions and new insights.

Authors:  Avedis Kazanjian; Eleanore A Gross; H Leighton Grimes
Journal:  Crit Rev Oncol Hematol       Date:  2006-05-23       Impact factor: 6.312

10.  Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.

Authors:  Yash Somnay; Herbert Chen; Muthusamy Kunnimalaiyaan
Journal:  Neuroendocrinology       Date:  2012-09-04       Impact factor: 4.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.